GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
GT BIOPHARMA, INC. (GTBP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $2.18 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $2.18M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $12.90M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $281.00K.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $25.40M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $2.18M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $12.90M 10-K · filed 2026-03-02 |
| 2025-09-30 | $281.00K 10-Q/A · filed 2026-03-06 |
| 2025-06-30 | $25.40M 10-Q/A · filed 2026-03-06 |
| 2025-03-31 | $780.00K 10-Q · filed 2025-05-15 |
| 2024-12-31 | $22.00K 10-K · filed 2025-02-21 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-26 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-26 |
| 2022-09-30 | $0.00 10-Q · filed 2022-10-31 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |